Exp. Neurol. 8, 220 (1963 (3) . Second, the use of such vague statements as "reservations" and "theoretical objections" without revealing what these are, effectively prevents rebuttal. Whenever these terms are clarified, interested parties should be given an opportunity to reply.
One is forced to conclude that the "reservations" or "theoretical objections" held by Petricciani et al. (1) have failed to impress a substantial proportion of the scientific community including several major national control authorities. Furthermore, any "reservations" or "theoretical objections" that will be proposed by Petricciani 2) A substantial number (25 to 80 percent) of monkey kidneys processed for vaccine manufacture must be discarded because of extensive contamination with one or more of 20 known viruses.
3) The annual slaughter of monkeys for primary c,ultures has reached such proportions that several species are endangered (6 amples where DBS engages in activities in which serious conflicts of interest are bound to result. In my view, and in the view of others, no control authority should be in the business of developing products or product components that they themselves will ultimately control. Nor should any control authority be allowed to sit in judgment of products or product components when the choice is between substances developed by that control authority and those competing with it from other laboratories. Scientists' motivations being what they are (including those at DBS), they cannot help but comproniuse situations where DBS scientists are asked to choose between two "alternatives," one developed by them and the other by outside scientists. We find just such a situation unfolding now, that is, monkey cell populations developed under contract to DBS, and quite naturally advocated by them, as compared to WI-38 developed by others and for which DBS even 10 years later still has "reservations" and "theoretical objections." It is by just such activities that the credibility gap between DBS and its constituency widens as they abrogate the very confidence on which their control authority rests.
As Petricciani et al. quite rightly point out in respect to passaged monkey cells, "further evaluation by other independent investigators will be necessary to increase the level of confidence in the safety of these cells." It is to be hoped that these important studies will be done exhaustively and that the decade of WI-38 vaccine testing required by DBS to increase their level of oonfidence in WI-38 will be equally applicable to vaccines prepared in DBS-FCL-1 and DBS-FRhL-2.
LEONARD developed from human, nonhuman primate and other animal sources so that, as more information is obtained and the need for a wider variety of vaccines is apparent, we will have an ample number and variety of systems with which to work. A number of participants pointed out that we should not have all our eggs in one basket" (1).
One year later (1968) there was still no research activity in this area by any groups. The Division of Biologics Standards felt that, on the basis of the discussions and conclusions of the 1967 cell culture conference, it had an obligation to support studies to develop nonhuman diploid cell lines and began two such projects.
In our report (2) we were attempting to make available the information that diploid cells from nonhuman primates are now available to those who would study them. 
